Valuation : CalciMedica, Inc.

Market Cap 14.82M 12.75M 12M 10.96M 20.5M 1.4B 20.56M 142M 55.01M 718M 55.64M 54.43M 2.31B P/E 2026 *
-0.72x
P/E 2027 * -0.41x
Enterprise Value 14.82M 12.75M 12M 10.96M 20.5M 1.4B 20.56M 142M 55.01M 718M 55.64M 54.43M 2.31B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.47%
Yield 2026 *
-
Yield 2027 * -
1 day-1.36%
1 week-6.55%
Current month+1.40%
1 month-45.41%
3 months-48.98%
6 months-30.45%
Current year-93.41%
1 week 2
Extreme 2
2.47
1 month 2
Extreme 2
3.97
Current year 2
Extreme 2
36
1 year 2
Extreme 2
36
3 years 2
Extreme 2
41.9
5 years 2
Extreme 2
42.95
10 years 2
Extreme 2
42.95
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 73 2007-03-31
Chief Executive Officer 63 2019-08-31
Director of Finance/CFO 36 2024-10-31
Director TitleAgeSince
Chairman 85 2023-03-19
Chairman 63 -
Director/Board Member 54 2023-03-19
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 Free

Director

10,000 0.0293%
8/19/26 Free

Chief Technology Officer

248,972 0.7292%
8/19/26 Free

Director

10,000 0.0293%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%-6.55%-86.31%-86.50% 14.82M
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.38%+0.37%+32.66%+158.50% 27.91B
Weighted average by Cap. -1.52%+0.18%+42.28%+145.07%

Financials

2026 *2027 *
Net sales - -
Net income -12.75M -10.97M -10.32M -9.43M -17.63M -1.2B -17.68M -122M -47.32M -617M -47.86M -46.82M -1.99B -27.1M -23.32M -21.94M -20.05M -37.5M -2.56B -37.6M -259M -101M -1.31B -102M -99.56M -4.23B
Net Debt - -
Logo CalciMedica, Inc.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Employees
15
Date Price Change Volume
26-09-04 US$2.170 -1.36% 94,132
26-09-03 US$2.200 +4.76% 94,776
26-09-02 US$2.100 +5.00% 113,721
26-09-01 US$2.000 -6.54% 141,365
26-08-31 US$2.140 -7.84% 166,643
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.170USD
Average target price
50.00USD
Spread / Average Target
+2,204.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CALC Stock